Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
Inspection included drug device combinations covering our recent filing in nasal sprays domain
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
This marks the second indication for which gumokimab has gained NDA review acceptance
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
Subscribe To Our Newsletter & Stay Updated
